Mallinckrodt plc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.94
- Today's High:
- $8.35
- Open Price:
- $8.35
- 52W Low:
- $7.94
- 52W High:
- $18.1
- Prev. Close:
- $8.36
- Volume:
- 27803
Company Statistics
- Market Cap.:
- $227.20 million
- Book Value:
- 162.342
- Revenue TTM:
- $2.06 billion
- Operating Margin TTM:
- -0.77%
- Gross Profit TTM:
- $891.70 million
- Profit Margin:
- -40.92%
- Return on Assets TTM:
- -0.13%
- Return on Equity TTM:
- -58.39%
Company Profile
Mallinckrodt plc had its IPO on under the ticker symbol MNKPF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Mallinckrodt plc has a staff strength of 2,778 employees.
Stock update
Shares of Mallinckrodt plc opened at $8.35 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.94 - $8.35, and closed at $8.08.
This is a -3.35% slip from the previous day's closing price.
A total volume of 27,803 shares were traded at the close of the day’s session.
In the last one week, shares of Mallinckrodt plc have slipped by -12.84%.
Mallinckrodt plc's Key Ratios
Mallinckrodt plc has a market cap of $227.20 million, indicating a price to book ratio of 0.0921 and a price to sales ratio of 0.1101.
In the last 12-months Mallinckrodt plc’s revenue was $2.06 billion with a gross profit of $891.70 million and an EBITDA of $690.40 million. The EBITDA ratio measures Mallinckrodt plc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Mallinckrodt plc’s operating margin was -0.77% while its return on assets stood at -0.13% with a return of equity of -58.39%.
In Q3, Mallinckrodt plc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 14.2%.
Mallinckrodt plc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-8.184 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mallinckrodt plc’s profitability.
Mallinckrodt plc stock is trading at a EV to sales ratio of 1.4714 and a EV to EBITDA ratio of -6.3081. Its price to sales ratio in the trailing 12-months stood at 0.1101.
Mallinckrodt plc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.26 billion
- Total Liabilities
- $779.10 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $15.60 million
- Dividend Payout Ratio
- 0%
Mallinckrodt plc ended 2024 with $6.26 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.26 billion while shareholder equity stood at $1.85 billion.
Mallinckrodt plc ended 2024 with $1.50 million in deferred long-term liabilities, $779.10 million in other current liabilities, 100000.00 in common stock, $-348600000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $391.20 million and cash and short-term investments were $391.20 million. The company’s total short-term debt was $44,100,000 while long-term debt stood at $3.03 billion.
Mallinckrodt plc’s total current assets stands at $2.17 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $377.00 million compared to accounts payable of $89.10 million and inventory worth $1.07 billion.
In 2024, Mallinckrodt plc's operating cash flow was $0 while its capital expenditure stood at $15.60 million.
Comparatively, Mallinckrodt plc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $8.08
- 52-Week High
- $18.1
- 52-Week Low
- $7.94
- Analyst Target Price
- $
Mallinckrodt plc stock is currently trading at $8.08 per share. It touched a 52-week high of $18.1 and a 52-week low of $18.1. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $12.08 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 3675% are held by institutions.
Frequently Asked Questions About Mallinckrodt plc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.